Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Quince Therapeutics, Inc. (QNCX) had Stock-Based Compensation of $5.11M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-39.46M |
|
-- |
|
-- |
|
$19.35M |
|
$-19.35M |
|
$-16.96M |
|
$-36.31M |
|
$-36.31M |
|
$-39.46M |
|
$-39.46M |
|
$-39.46M |
|
$-39.46M |
|
$-19.35M |
|
$-19.50M |
|
50.10M |
|
50.10M |
|
$-0.75 |
|
$-0.75 |
|
| Balance Sheet Financials | |
$22.90M |
|
$0.59M |
|
$70.63M |
|
$93.52M |
|
$43.23M |
|
-- |
|
$86.01M |
|
$129.24M |
|
$-35.71M |
|
$-103.53M |
|
$-35.71M |
|
55.73M |
|
| Cash Flow Statement Financials | |
$-41.42M |
|
$23.23M |
|
$17.91M |
|
$6.21M |
|
$5.81M |
|
$-0.40M |
|
|
Stock-Based Compensation |
$5.11M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.53 |
|
-- |
|
-- |
|
-- |
|
-0.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-41.78M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
110.48% |
|
38.11% |
|
-42.19% |
|
110.48% |
|
$-0.64 |
|
$-0.83 |
|
$-0.83 |
|